If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
HEPATOLOGY
ISSN 2053-4221 May 2013 • emjreviews.com
INSIDE
Review of The International
Liver Congress™ 2013:
the 48th Annual Meeting of EASL
Amsterdam, The Netherlands
HEPATOLOGY
Contents
EDITORIAL PANEL........................................................................................................................................................4
CONGRESS REVIEW......................................................................................................................................................8
• Review of The International Liver CongressTM, the 48th Annual Meeting of the European
Association for the Study of the Liver, held in Amsterdam, The Netherlands, 24th-28th April 2013
HEPATIC ENCEPHALOPATHY: A PARADIGM SHIFT.........................
HEPATOLOGY ISSN 2053-4221
HEPATOLOGY Contents EDITORIAL PANEL............
IL28B POLYMORPHISMS IN INTERFERON-TREATED PATIEN
HEPATOLOGY Editorial Panel Prof. Paolo Angeli A
HEPATOLOGY Publisher Claire Gore Editorial Di
Robust protection against recurrent episodes of h
Foreword Prof. Dr. Markus Peck-Radosavljevic
EASL ANNUAL MEETING 2013 THE INTERNATIONAL LIVER
Welcome to the European Medical Journal review of
EASL ANNUAL MEETING 2013 THE INTERNATIONAL LIVER
URNAL REVIEW OF EASL’S 48TH ANNUAL IVER CONGRES
EASL ANNUAL MEETING 2013 THE INTERNATIONAL LIVER
THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIV
EASL ANNUAL MEETING 2013 THE INTERNATIONAL LIVER
L, WEIGHT AND LIVER DISEASE SHOWS OPE, THE HARDES
EASL ANNUAL MEETING 2013 THE INTERNATIONAL LIVER
LIVERTREETM TO BE ONE-STOP WEBSITE FOLLOWING the
EASL ANNUAL MEETING 2013 THE INTERNATIONAL LIVER
CARDIO AIDS POTENTIAL CANCER CURE REGULAR
HEPATIC ENCEPHALOPATHY: A PARADIGM SHIFT Summary
Liver cirrhosis Control HE no H
Survival 1.0 0.8 0.6 0.4 0.2 0.0 0 Survi
30 Compensated (N=114)
syndrome that is referred to as acute or chronic
Patient with possible overt HE Not HE: Alt
Rifaximin is used for secondary prophylaxis, and
showed that overall antibiotics produced a positi
Placebo Xifaxan® 550mg Overall
REFERENCES 1. Häussinger D. Low grade cereb
induced ototoxicity. Curr Pharm Des. 2007;13(
The revolution continues At Philips, we strive f
ADRENAL INSUFFICIENCY (AI) IN CIRRHOSIS Julia O’
plasma cortisol is measured, which is a surrogate
diseases such as alcoholic liver disease, primary
and free cortisol concentrations. Over the last y
with steroid sparing regimen31 and after steroid
of serum-free and salivary cortisol. Liver Intern
ACUTE-ON-CHRONIC LIVER FAILURE: APPLYING THE
• Male gender • Higher bilirubin level • Lo
generate an adequate immune response due to a dys
The PIRO concept of acute on chronic liver failur
REFERENCES 1. Sen S, Williams R, Jalan R.
F, Neff G, Leevy CB, Sigal S, et al. Rifaximin tr
CELLULAR CONSEQUENCES OF Z ALPHA-1 ANTITRYPS
Figure 1. Polymerisation of Z-alpha-1 antitrypsin
Lung Disease in Z α -Antitrypsin Deficiency
Activation of the ER-Overload Response in Severe
Figure 4A. 4M dissociates intracellular Z-AT poly
between pathogenesis of liver and lung disease in
REFERENCES 1. Stoller J K, Aboussouan L S. A rev
secretion impaired glycoprotein into distin
IL28B POLYMORPHISMS IN INTERFERON-TREATED
100 80 60 40 % Patients with HBeAg seroconver
p<0.001). IL28B genotypes were also independently
TT patients. The 42 rs12979860 CT patients with t
REFERENCES 1. EASL Clinical Practice Guideli
discover Now the…
MANAGEMENT OF HEPATITIS B VIRUS INFECTION IN
i. Resistance/mutation to oral antiviral dru
3 of 651 (0.5%) recipients when donors were anti-
Adefovir (10mg/day or 5mg/day in presence of rena
Hepatitis B Immunoglobulin Nucleoside/Nucleotid
(iv) Alternatives to standard HBIG dose This incl
body weight of <75Kg & >75Kg respectively) of HBI
Y, Livni N, Tur-Kaspa R. Sanctuary of hepatitis B
Proc. 2007;39(5):1533-6. 48. Xiong X, Flores C, Y
83. Yi NJ, Choi JY, Suh KS, et al. Post- transpla
VIRAL PROTEINS MEDIATE UPREGULATION OF
1 Positive for anti-HCV antibodies 2 Nega
(A) (B)
evaluated by analysis of dot plots or histograms
*** 3 2 Fold increase in MFI 1 0 HC CH
(A)
This has brought in a state of ambiguity to the s
might be related to up-regulation of SOCS3.39 The
MaWhinney S, Wilson CC. Influence of plasma viremi
The revolution continues At Philips, we strive f
TOWARDS A STANDARDISED METHOD TO ACQUIRE AND STO
to acceptance and implementation in the sci
MATERIAL AND METHODS A PubMed search was perform
Best Variation
data will be much more reliable, and since refere
2012;56:869-76. 18. Nault J C, Fabre M, Couchy G,
Hepatol. 2007;46:151-9. 56. Omenetti A, Bass L M,
Robust protection against recurrent episodes of h
WHAT’S NEW NEW DRUG STIMULATES IMMUNE SYSTEM TO K
HEPATOLOGY 19-YEAR-OLD WOMAN NEARING FULL PREGNAN
WHAT’S NEW “GAME-CHANGING” HEPATITIS C VIRUS DRUG
HEPATOLOGY LIFETIME COPIOUS COFFEE CONSUMPTION NO
FEATUREDSUPPLIERS FEATURED SUPPLIERS Norgine is
HEPATOLOGY BUYER’S GUIDE ABBOTT
UPCOMING EVENTS & COURSES EVENTS APASL Liver Wee
HEPATOLOGY COURSES EASLClinicalSchoolofHepatolog
From a host of fourteen therapeutical areas, EURO